Moderna: posts loss for Q4

(CercleFinance.com) - Moderna reports a loss per share of $2.
91 for the Q4 2024, compared with EPS of $0.55 a year earlier, reflecting net product sales divided by three y-o-y to $938m. NB: pmt -4.5%.

It says the decline is mainly attributable to the early US launch of its updated Covid-19 vaccine in Q3, with FDA approval granted three weeks earlier than the previous year.

Our team successfully filed three biologics license applications in the final months of the year, and reduced our costs by 27% in 2024 compared with 2023, the messenger RNA vaccine specialist said.

Posting a net loss of $9.28 for FY 2024, and revenues of $3.2bn, Moderna expects revenues of $1.5bn to $2.5bn for 2025, with an expected final cash balance of around $6bn.


Copyright (c) 2025 CercleFinance.com. All rights reserved.